Stemline Therapeutics Inc (NASDAQ:STML) Expected to Announce Earnings of -$0.47 Per Share

Analysts expect Stemline Therapeutics Inc (NASDAQ:STML) to report earnings of ($0.47) per share for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Stemline Therapeutics’ earnings, with estimates ranging from ($0.54) to ($0.38). Stemline Therapeutics posted earnings per share of ($0.66) during the same quarter last year, which indicates a positive year over year growth rate of 28.8%. The company is expected to announce its next earnings report on Thursday, August 8th.

On average, analysts expect that Stemline Therapeutics will report full year earnings of ($2.09) per share for the current year, with EPS estimates ranging from ($3.01) to ($1.55). For the next financial year, analysts expect that the firm will report earnings of $0.29 per share, with EPS estimates ranging from ($1.25) to $2.12. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Stemline Therapeutics.

Stemline Therapeutics (NASDAQ:STML) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.67) by ($0.06). The firm had revenue of $5.05 million during the quarter, compared to analyst estimates of $2.61 million.

Several research analysts have recently weighed in on STML shares. Wedbush restated a “buy” rating and set a $95.00 target price on shares of Global Blood Therapeutics in a report on Monday, May 13th. ValuEngine upgraded Vermillion from a “hold” rating to a “buy” rating in a report on Wednesday, May 15th. Roth Capital restated a “buy” rating on shares of Resverlogix in a report on Thursday, May 23rd. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 4th. Finally, HC Wainwright set a $35.00 price target on shares of Stemline Therapeutics and gave the company a “buy” rating in a research report on Thursday, June 20th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $25.20.

In other Stemline Therapeutics news, COO Kenneth Hoberman sold 25,817 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The stock was sold at an average price of $14.27, for a total value of $368,408.59. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Ivan Bergstein sold 56,316 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total value of $849,245.28. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 149,177 shares of company stock worth $2,236,377. Corporate insiders own 13.10% of the company’s stock.

Large investors have recently bought and sold shares of the business. Rhumbline Advisers raised its holdings in shares of Stemline Therapeutics by 47.2% during the fourth quarter. Rhumbline Advisers now owns 37,138 shares of the biopharmaceutical company’s stock valued at $353,000 after acquiring an additional 11,911 shares during the period. BlackRock Inc. grew its position in Stemline Therapeutics by 4.9% in the fourth quarter. BlackRock Inc. now owns 2,065,239 shares of the biopharmaceutical company’s stock worth $19,618,000 after acquiring an additional 95,747 shares in the last quarter. Bank of New York Mellon Corp grew its position in Stemline Therapeutics by 26.5% in the fourth quarter. Bank of New York Mellon Corp now owns 134,756 shares of the biopharmaceutical company’s stock worth $1,281,000 after acquiring an additional 28,198 shares in the last quarter. Great West Life Assurance Co. Can acquired a new stake in shares of Stemline Therapeutics in the fourth quarter worth $47,000. Finally, Dimensional Fund Advisors LP lifted its stake in shares of Stemline Therapeutics by 8.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 185,395 shares of the biopharmaceutical company’s stock worth $1,761,000 after buying an additional 14,275 shares during the last quarter. Institutional investors and hedge funds own 77.66% of the company’s stock.

Shares of Stemline Therapeutics stock traded up $0.32 on Friday, hitting $13.34. 5,220 shares of the company were exchanged, compared to its average volume of 392,389. The stock has a market cap of $586.25 million, a PE ratio of -4.41 and a beta of 1.33. The stock’s 50-day moving average is $14.27. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $17.85. The company has a quick ratio of 5.03, a current ratio of 5.07 and a debt-to-equity ratio of 0.01.

Stemline Therapeutics Company Profile

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Story: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Stemline Therapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.